We investigated the p53 status and the ability of exogenous wildtype (wt) p53 to affect chemosensitivity in three anaplastic thyroid carcinoma cell lines (BHT-101, SW-1736, and KAT-4). All three cell lines had nonfunctional p53. Treatment with mitomycin C or adriamycin did not result in accumulation of p53 or induction of p21 WAF1/CIP1 or Mdm-2 and did not cause Rb dephosphorylation. BHT-101 and KAT-4 cells had mutant p53. SW-1736 cells were functionally mutant because of marked down-regulation of wt p53 messenger ribonucleic acid, representing a novel mechanism of p53 dysfunction. Infection with a p53-expressing adenovirus (Ad-p53) induced high levels of p21 and Mdm-2 proteins. In BHT-101 cells, induction of p21 and Mdm-2 was evident 10 h after infection. In KAT-4 cells, induction of p21 and Mdm-2 was observed 1 day after infection, and continued to increase over the ensuing 24 h. SW-1736 cells demonstrated intermediate kinetics. Sensitivity to the cytotoxic effect of Ad-p53 paralleled the kinetics of p21/Mdm-2 induction. BHT-101 cells were most sensitive to killing by Ad-p53, with an IC 50 of less than 2 multiplicity of infection; SW-1736 cells were intermediate in sensitivity; KAT-4 cells were resistant. All three cell lines became more sensitive to adriamycin after wt p53 expression, with a 10-fold decrease in IC 50 values. The latter observation may make a combination of wt p53 and chemotherapeutic drugs an attractive modality for treating anaplastic thyroid cancer. (J Clin Endocrinol Metab 83:
A NAPLASTIC thyroid carcinoma, recognized as one of the most aggressive malignant tumors in humans, frequently fails to respond to available chemotherapeutic agents (1, 2) . Dedifferentiation of these cancer cells is characterized by the absence of expression of thyroid-specific genes (thyroglobulin, thyroid peroxidase, and TSH receptor). This results in their inability to incorporate radioactive iodine and precludes this tissue-selective modality for treatment.
Although the molecular changes responsible for the aggressive behavior remain to be elucidated, a consistent observation has been a higher frequency of mutations in the p53 tumor suppressor gene in anaplastic thyroid cancers (3) . Thus, in one study using immunohistochemistry, p53 expression was found in 62.5% of undifferentiated carcinomas, but in only 5% of other types of thyroid carcinomas (4); in another report, p53 was detected in 11.1% of well differentiated, 40.9% of poorly differentiated, and 63.6% of undifferentiated carcinomas (5) . As mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, including anaplastic thyroid cancers, it appears that alterations in p53 represent a late genetic event in human thyroid carcinogenesis (6) . Based on these data, it has been proposed that mutations in the p53 gene are responsible for the progression from differentiated into anaplastic carcinoma (7) (8) (9) . Moreover, it has been demonstrated that introduction of wild-type (wt) p53 can induce differentiation in some thyroid cancer cell lines (10, 11) .
The aggressive clinical behavior of anaplastic thyroid cancer includes a lack of sensitivity to the majority of available chemotherapeutic agents. Although it is likely this resistance is multifactorial, it may be explained to some extent by the high frequency of p53 mutations, as wt p53 may be important for apoptosis and growth arrest after the administration of DNA-damaging drugs (12, 13) .
In the present study we report three anaplastic thyroid cancer cells lines with nonfunctional p53 characterized by a lack of induction after exposure to DNA-damaging drugs. To further address the role of p53 in anaplastic thyroid carcinomas, we employed a p53-expressing adenovirus (Ad-p53). Introduction of wt p53 resulted in the induction of p21 and Mdm-2, confirming that the pathway downstream of p53 was intact. Furthermore, introduction of wt p53 increased sensitivity to adriamycin and cisplatin in all three anaplastic thyroid cancer cell lines.
Palyi (National Institute of Oncology, Budapest, Hungary). SW-1736 was developed by Drs. Leibowitz and McCombs III at the Scott and White Memorial Hospital (Temple, TX) in 1977 and was provided by Nils-Erik Heldin (Uppsala University, Uppsala, Sweden). KAT-4 was developed and maintained in one of our laboratories (that of K.B.A.). The three cell lines were maintained in RPMI medium containing 10% FBS.
Adenovirus infections
Ad-lacZ, a ␤-galactosidase expressing replication-deficient adenovirus, and Ad-p53, a wild-type p53-expressing replication-deficient adenovirus, were gifts from Dr. Bert Vogelstein (Johns Hopkins University, Baltimore, MD). Adenovirus titers were determined by plaque formation after infection of 293 cells. The multiplicity of infection (MOI) was defined as the ratio of the total number of plaque-forming units used in a particular infection divided by the number of cells. X-Galactosidase staining of Ad-lacZ-infected tumor cells was performed 1 day after infection (14) .
PCR amplification and sequence analysis of p53 and ␤-tubulin
RT of 1 g total ribonucleic acid (RNA) was performed using a primer complimentary to p53 sequences downstream of exon 9: 5Ј-1022 GTTC-CGAGAGCTGAATGAGGC 1042 -3Ј. PCR amplifications of p53 were performed using 2.5 mmol/L MgCl 2 , an annealing temperature of 55 C for 40 cycles, and a primer upstream of exon 5: 5Ј-339 TTCTTGCATTCTGG-GACAGCC 359 -3Ј together with the primer used in the RT reaction. Using RNA from SW-1736 cells, a PCR product was not obtained even after 45 cycles of PCR amplification. Therefore, for SW-1736 RNA, PCR amplification of p53 was performed using two different sets of primers that 
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gave smaller PCR products, allowing for amplification and sequencing of p53 exons 5-9. The primer pairs used in these reactions included: A, the primer corresponding to residues 339 -359 as the 5Ј-primer together with a primer complimentary to residues 786 -804 as the 3Ј-primer 5Ј-786 GGTAATCTACTGGGACGGA 804 -3Ј; and B, a primer corresponding to residues 751-770 ( 751 CCATCCTCACCATCATCAC 770 ) as the 5Ј-primer together with the primer complimentary to residues 1022-1042 as the 3Ј-primer. PCR product was purified with PCR Select-III spin columns (5 Prime-3 Prime, Boulder, CO) and directly sequenced with the Taq DyeDeoxy Terminator Cycle Sequencing Kit following the manufacturer's instructions (Applied Biosystems, Foster City, CA). Two primers were used for sequencing in addition to the above-described primers: a primer corresponding to residues 569 -588 ( 569 CCTCCTCAGCATCT-TATCC 588 ) and a primer complimentary to residues 686 -706 ( 686 CTG-TACCACCATCCACTACAA 706 ). The reaction products were purified with Centri-Sep spin purification columns (Princeton Separations, Adelphia, NJ), electrophoresed on 48-cm 4.75% polyacrylamide/urea gels, and analyzed by an automated DNA sequencing system (model 377A, Applied Biosystems). PCR amplification of the widely expressed isotype of ␤-tubulin M40 was performed as previously described (15) .
Immunoblot analysis
Cells plated at a density of 4 ϫ 10 5 /well in six-well plates were treated with drugs or infected with adenovirus. After incubation for the indicated times, cells were lysed and 20 g protein were separated by electrophoresis through 12.5 (p21, p53, and tubulin) or 7.5% SDS-PAGE gels (Rb, Mdm-2, and p53) as previously described (15) . Immunoblotting was performed using mouse antihuman WAF-1 (EA10), p53 (PAb 1801), Rb, and Mdm-2 (Oncogene Science, Cambridge, MA) as previously described (16) .
Growth inhibition and cell viability
Cells were plated at a density of 2500 -5000/well in 96-well plates in 0.1 mL medium in triplicate. Twenty-four hours later, adenovirus infection was performed as described above. Chemotherapeutic drugs were added 1 h after adenovirus infections. Three days later, MTT viability assays were performed (14) .
Results

p53 in anaplastic thyroid cancer cell lines is nonfunctional
Under normal circumstances, wt p53 protein accumulates after treatment with DNA-damaging agents and induces the transcription of target genes, including p21 WAF1/CIP1 and mdm-2. Induction of p21, in turn, inactivates cyclin-dependent kinases that phosphorylate Rb, resulting in its dephosphorylation. Therefore, accumulation of p53 protein, induction of p21 and Mdm-2, and dephosphorylation of Rb are markers of a functional p53.
The levels of p53 protein were highest in KAT-4 cells, a hallmark of mutant p53; intermediate levels were observed in BHT-101 cells, and very low to undetectable levels were found in SW-1736 cells (Fig. 1) . Furthermore, treatment with either adriamycin or mitomycin C did not increase p53 levels or result in detectable p21 or Mdm-2 and did not cause Rb dephosphorylation. Therefore, p53 is functionally inactive in all three cell lines. In agreement with this, sequence analysis revealed mutant p53 status in two of the three cell lines with a substitution in codon 251 in BHT-101 (ATC3 ACC; Ile3 Thr) and a substitution in codon 273 in KAT-4 (CGT3 CAT; Arg3 His). A mutation could not be identified in RNA from SW-1736 cells, which was found on sequence analysis to be wt in exons 5-9. However, as shown in Fig. 2 , consistent with the low levels of p53 protein, expression of p53 was markedly reduced, precluding normal p53 protein expression and function. This pseudo-null p53 status of SW-1736 was functionally equivalent to a p53 null phenotype.
Exogenous wt p53 induces p21 and Mdm-2
Infection of the BHT-101 and SW-1736 cell lines with an adenovirus containing wt p53 (Ad-p53) resulted in rapid accumulation of p53 protein by 10 h (Fig. 1C) . In KAT-4 cells, the increase in p53 protein was not readily apparent because of the very high levels of endogenous p53. In all three cell lines, introduction of wt p53 resulted in induction of p21 and Mdm-2 proteins, indicating that the lack of p21 and Mdm-2 induction after DNA-damaging drugs was a consequence of a nonfunctional p53 and not defective mdm-2 or p21. Induction of p21 reached maximal levels 1 day after infection of BHT-101 or SW-1736 cells, but not KAT-4 cells (Fig. 3) . With KAT-4 cells it was possible to obtain comparable induction using a higher dose of Ad-p53 (40 MOI) or a longer incubation time (48 h). Although it has been suggested that deletion of p21 may be involved in thyroid carcinogenesis (17) , in all three cell lines we found defects in p53, but not p21.
Kinetics of p21/Mdm-2 induction determines sensitivity to p53
The differential sensitivity to Ad-p53 cytotoxicity correlated with the kinetics of induction of p53-responsive proteins. BHT-101 and SW-1736 cells were sensitive to p53. In these two cell lines, induction of both p21 and Mdm-2 after reintroduction of wt p53 occurred within 10 h, and in BHT-101 cells it began to decline by 40 h. In contrast, induction of p21 in KAT-4 cells was delayed (Fig. 3) . Quantitatively, 3 days after infection with 2 MOI of Ad p53, only 50% of BHT-101 cells were alive. SW-1736 cells were also very sensitive to Ad p53, with a 50% survival 3 days after infection with 8 MOI of Ad p53. The cytotoxicity of Ad-p53 was p53 specific, as shown in Fig. 3C , which depicts the lack of a significant cytotoxic effect of a control Ad-lacZ adenovirus lacking p53 even at a MOI of 64. In contrast, KAT-4 cells were as resistant to Ad-p53 as they were to Ad-lacZ.
Resistance of KAT-4 cells to Ad-p53 is associated with low infectivity
Although the high levels of nonfunctional p53 present in KAT cells could explain the blunted induction of p53-inducible proteins, we considered the possibility that, instead, low infectivity could explain these observations. The expression of p53 was not considered a reliable marker because of the very high levels of endogenous mt p53 in KAT-4 cells. Therefore, we compared the expression of ␤-galactosidase after infection with a ␤-galactosidase-expressing adenovirus (AdlacZ). Expression of Ad-lacZ required a 10-fold higher MOI in KAT-4 cells than in BHT-101 cells (Fig. 4) . Nearly all BHT-101 cells were infected at a MOI of 2 (Fig. 4B) , with increased intensity of staining observed with increasing MOI. In contrast, about 10% of KAT-4 cells stained for ␤-galactosidase at a MOI of 2 (data not shown), whereas the majority of cells were positive only when a MOI of 20 was used (Fig. 4C) . As all KAT-4 cells were infected at a MOI above 20, we can conclude that KAT-4 cells were refractory to p53-mediated cytotoxicity.
Expression of wt p53 increases sensitivity to adriamycin
To determine whether wt p53 could enhance drug cytotoxicity, we infected cells with Ad-p53 and examined drug sensitivity after infection ( mately 20 ng/mL, but a MOI of 64 was required to achieve comparable sensitization with KAT-4 cells.
Morphological alterations of SW-1736 cells by p53 and adriamycin
Although SW-1736 cells underwent morphological changes after infection with wt p53 (Fig. 6) , no induction of messenger RNA (mRNA) for TSH receptor, thyroglobulin, or thyroid peroxidase expression could be demonstrated by PCR (data not shown). Therefore, introduction of wt p53 caused p53-specific, but not tissue-specific, responses that correlated with the cytotoxic effects of p53 in these cells. In addition, treatment with adriamycin resulted in marked morphologic alterations (Fig. 6) .
Discussion
Early thyroid tumor development has been correlated with mutations in five different genes: ras, ret, trk, gsp, and TSH receptor (3) . Although the molecular events responsible for progression to anaplastic cancer remain to be fully defined, persuasive evidence supports a role for the tumor suppressor gene, p53. In several studies, mutations in p53 or increased expression consistent with a mutant p53 protein have been associated with the progression from differentiated to anaplastic carcinoma (3) (4) (5) (6) (7) (8) (9) .
Although emphasis has been placed on the possible role of p53 mutations in thyroid dedifferentiation, p53 mutations may also contribute to the resistance of anaplastic carcinoma to chemotherapy. In the present study we demonstrate that treatment with DNA-damaging drugs did not result in induction of p53 or stimulation of the downstream genes, p21
and mdm-2. Reintroduction of wt p53 using an adenovirus vector was able to induce these changes. Moreover, the cellular response correlated with the cytotoxicity of Ad-p53. BHT-101 and SW-1736 were very sensitive to the cytotoxic effect of Ad-p53, with IC 50 values of 2 and 8 MOI, respectively. In contrast, a delayed and blunted response of KAT-4 cells to p53 correlated with a low cytotoxicity of Ad-p53 against these cells. The resistance of KAT-4 cells to Ad-p53 can be explained in at least two nonmutually exclusive ways. The first is a low infectivity of KAT-4 cells. Indeed, 10-fold higher doses of Ad-lacZ were needed to achieve the same degree of ␤-galactosidase staining in KAT-4 as in BHT-101 cells. Second, expressed wt p53 may be blocked by mutant p53 (18) or Mdm-2 (19) proteins, both of which were expressed at high levels in KAT-4 cells.
Although p53 caused marked morphological changes in SW-1736 cells, we did not find reexpression of thyroidspecific TSH receptor or thyroglobulin. This contrasts with previous observations in cells stably transfected with a temperature-sensitive murine p53 that reacquired the ability to respond to TSH stimulation (10) . However, as ARO cells are not anaplastic and express thyroid-specific genes before transfection, a direct comparison is not possible. In a separate study, papillary carcinoma cells stably transfected with wt p53 were shown to express thyroid peroxidase (TPO). However, as emphasized by the researchers, the yield of transfectants was low, and only one wt p53-overexpressing clone that expressed TPO was isolated (11) . Moreover, wt p53 did not directly stimulate the transcriptional activity of a TPO promoter construct (11) . The possibilities that the expression of wt p53 is better tolerated by well differentiated thyroid p53 ENHANCES CHEMOSENSITIVITY OF ANAPLASTIC THYROID CELLScells, and that the expression of wt p53 led to the selection of a well differentiated papillary carcinoma clone cannot be excluded. Additional studies, consistent with this limited effect of wt p53 expression on thyroid differentiation, showed that inactivation of wt p53 by mt p53 did not result in an anaplastic phenotype, although loss of some tissuespecific markers was reported (3). The results in the present study and the available data suggest that p53 that does not directly control the expression of thyroid-specific genes. However, genomic instability secondary to mt p53 may lead to dedifferentiation and thus could explain the clinical observation that a majority of anaplastic thyroid carcinomas have mutant p53. Alternately, loss of wt p53 function could permit the growth of rapidly growing anaplastic cells that would otherwise be eliminated by wt p53.
Although the problem facing physicians treating anaplastic thyroid carcinoma is a systemic dissemination of disease, this tumor often presents as locally advanced disease, requiring multimodality therapy (2) . Adjuvant chemotherapy and radiotherapy have been used in attempts to enhance local control, with only moderate success (2) . The present study suggests that although p53 expression may not have a significant impact on the differentiation of anaplastic thyroid carcinomas, it may have a role in chemosensitivity. The advent of therapeutic strategies that target molecular markers such as p53 may provide additional treatment options in patients with localized anaplastic thyroid carcinoma. Such approaches are being actively investigated in head and neck cancers, and have targeted the p53 gene either by attempting to eradicate cells expressing mutant p53 (20) or by trying to restore normal function (21) . Here we showed that expression of wt p53 increased the sensitivity of all three cell lines to adriamycin (10-fold decrease in IC 50 ). Similarly, wt p53 increased the sensitivity of KAT-4 cells to cisplatin (not shown). Local administration of Ad-p53 in conjunction with systemic therapy with DNA-damaging drugs could be useful in the treatment of locally advanced anaplastic carcinomas.
Finally, we did observe that adriamycin and cisplatin induced morphological alterations in SW-1736 cells. A previous study reported conversion of noniodine-concentrating differentiated thyroid carcinoma metastasis into iodineconcentrating foci after anticancer chemotherapy (22) . The patient presented with metastatic papillary carcinoma and was treated with cisplatin and doxorubicin. Repeat 131 I imaging after three cycles of chemotherapy showed significant 131 I uptake in previously noniodine-concentrating lesions. Although these must be regarded as preliminary observations, additional studies are planned to determine whether the combination of chemotherapy and wt p53 can cause differentiation.
